Daina Graybosch
Stock Analyst at Leerink Partners
(0.80)
# 3,703
Out of 4,734 analysts
118
Total ratings
34.09%
Success rate
-14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $97.92 | +21.53% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $0.94 | +112.77% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.51 | +95.08% | 8 | May 15, 2024 | |
| TSVT 2seventy bio | Upgrades: Outperform | $5 → $18 | $2.61 | +589.66% | 5 | Jan 31, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $66.48 | -41.34% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.89 | +236.32% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.91 | +1,439.65% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.27 | +687.40% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $1.15 | +5,117.39% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $1.69 | +432.54% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $14.03 | +170.85% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $5.56 | +44.01% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $111.93 | +100.13% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.47 | +1,114.57% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $8.00 | +637.50% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.33 | +1,178.20% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.25 | +300.00% | 4 | Feb 25, 2022 |
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $97.92
Upside: +21.53%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $0.94
Upside: +112.77%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.51
Upside: +95.08%
2seventy bio
Jan 31, 2024
Upgrades: Outperform
Price Target: $5 → $18
Current: $2.61
Upside: +589.66%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $66.48
Upside: -41.34%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.89
Upside: +236.32%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.91
Upside: +1,439.65%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.27
Upside: +687.40%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $1.15
Upside: +5,117.39%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $1.69
Upside: +432.54%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $14.03
Upside: +170.85%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $5.56
Upside: +44.01%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $111.93
Upside: +100.13%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.47
Upside: +1,114.57%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $8.00
Upside: +637.50%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.33
Upside: +1,178.20%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.25
Upside: +300.00%